Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | RGS12 | O14924 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11142447 | 0.79 | CYP2D6 (0.47) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| SCHEMBL5867158 | 0.75 | HTR2A (0.48) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| SCHEMBL2323888 | 0.74 | TSHR (0.45) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| Hydrochloric Acid SCHEMBL6240205 | 0.73 | KMT2A (0.50) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| SCHEMBL17274525 | 0.73 | TDP1 (0.38) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| Racephedrine SCHEMBL8728630 | 0.73 | ADRA2C (0.71) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| Pseudoephedrine SCHEMBL8728628 | 0.73 | ADRA2C (0.71) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| Racephedrine SCHEMBL2081241 | 0.73 | ADRA2C (0.71) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| Racephedrine SCHEMBL8017708 | 0.73 | ADRA2C (0.71) | CYP2D6CYP3A4PKMADRA1ACYP2C19 | |
| Pseudoephedrine SCHEMBL2081239 | 0.73 | ADRA2C (0.71) | CYP2D6CYP3A4PKMADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230194486-A1 | QUANTITATIVE CHIRALITY AND CONCENTRATION SENSING OF CHIRAL ANALYTES USING A RELAY ASSAY | NATIONAL SCIENCE FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10246430-B2 | Methods for producing Beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180265490-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2018-09-20 | — | — | US | disclosed |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | LUNG BIOTECHNOLOGY PBC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | LUNG BIOTECHNOLOGY PBC (US) | 2017-06-15 | — | — | US | disclosed |
| US-8334385-B2 | Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof | GLENMARK GENERICS LIMITED | 2012-12-18 | — | — | US | disclosed |
| US-20100317856-A1 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | GLENMARK GENERICS LTD (IN) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265490-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | CYP2D6 528/4885CYP3A4 478/4885PKM 1318/4885 |
| US-20170166545-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | CYP51A1, COASY, BLVRB | CYP2D6 41/4885CYP3A4 28/4885PKM 695/4885 |
| US-10246430-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | CYP2D6 528/4885CYP3A4 478/4885PKM 1318/4885 |
| US-20100317856-A1 | PROCESS FOR THE PREPARATION OF R-SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | DPP4, DPP9, DPP3 | CYP2D6 626/4885CYP3A4 44/4885PKM 1940/4885 |
| US-10005753-B2 | Methods for producing beraprost and its derivatives | CYP51A1, COASY, BLVRB | CYP2D6 41/4885CYP3A4 28/4885PKM 695/4885 |
| US-10640481-B2 | Methods for producing Beraprost and its derivatives | UMPS, GGPS1, DHPS | CYP2D6 528/4885CYP3A4 478/4885PKM 1318/4885 |
| US-20190202797-A1 | METHODS FOR PRODUCING BERAPROST AND ITS DERIVATIVES | UMPS, GGPS1, DHPS | CYP2D6 528/4885CYP3A4 478/4885PKM 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.